ASH 2023: Auto-HCT vs CAR T-Cell Therapy in Patients With LBCL
Posted: 01/17/2024 | By: Sarah Campen, PharmD

A study presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition compared the outcome of patients with large B-cell lymphoma (LBCL) who received chimeric antigen receptor (CAR) T-cell therapy vs autologous hematopoietic cell transplantation (auto-HCT) while in a complete response (Abstract 781).

Question 1 of 5

What was the rate of 2-year progression-free survival in patients with large B-cell lymphoma treated with CAR T-cell therapy compared with auto-HCT?

Choose 1